PharmaCielo Ltd. (TSXV:PCLO) (OTC:PCLOF), the Canadian parent of Colombia's cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced its financial results Friday for the second quarter ended June 30, 2024. The company reported a 390% increase in revenue year-over-year to CA$783,680 ($570,891), driven by increased sales of cannabis derivative products. Q2 2024 Financial Highlights Revenue was CA$783,680, compared to CA$159,539 in the second quarter of 2023. Net loss was CA$2.6 million, compared to the CA$3.6 million from Q2 2023. Adjusted EBITDA was a negative CA$592.000, an improvement compared to the CA$2.1 million in the same quarter of 2023. Gross profit was CA$274,745, rising from a loss of CA$609,254 in Q2 2023. PharmaCielo’s Net Loss Narrows Despite the growth in revenue, PharmaCielo’s net loss for ...